LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.93 -4.84

Buy Sell

Overview

Share price change

24h

Current

Min

3.84

Max

4.13

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+271.19% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-24M 231M
Previous open	8.77
Previous close	3.93

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 mar 2026, 23:01 UTC

Earnings

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5 mar 2026, 21:54 UTC

Earnings

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5 mar 2026, 21:35 UTC

Major Market Movers

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6 mar 2026, 00:00 UTC

Major News Events

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5 mar 2026, 23:46 UTC

Market Talk

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5 mar 2026, 23:33 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5 mar 2026, 23:27 UTC

Market Talk

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5 mar 2026, 22:54 UTC

Market Talk

Earnings

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5 mar 2026, 22:50 UTC

Market Talk

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5 mar 2026, 22:48 UTC

Earnings

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5 mar 2026, 22:46 UTC

Earnings

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5 mar 2026, 22:44 UTC

Earnings

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 mar 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 mar 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 mar 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

5 mar 2026, 21:35 UTC

Earnings

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 mar 2026, 21:32 UTC

Earnings

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 mar 2026, 21:26 UTC

Earnings

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5 mar 2026, 21:24 UTC

Earnings

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5 mar 2026, 21:23 UTC

Earnings

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5 mar 2026, 21:22 UTC

Earnings

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 mar 2026, 21:21 UTC

Earnings

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5 mar 2026, 21:21 UTC

Earnings

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5 mar 2026, 21:20 UTC

Earnings

Costco February Net Sales Were $21.69 B >COST

5 mar 2026, 21:20 UTC

Earnings

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 mar 2026, 21:20 UTC

Earnings

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 mar 2026, 21:19 UTC

Earnings

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5 mar 2026, 21:18 UTC

Earnings

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5 mar 2026, 21:18 UTC

Earnings

Costco 2Q Same-Store Sales Up 7.4% >COST

5 mar 2026, 21:15 UTC

Earnings

Costco 2Q EPS $4.58 >COST

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

271.19% upside

12 Months Forecast

Average 15.33 USD 271.19%

High 25 USD

Low 10 USD

Based on 3 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.